Bartell Drugs selects KSS Retail for price, promotion optimization
CINCINNATI — Seattle-based retail pharmacy chain Bartell Drugs will use KSS Retail’s price modeling and optimization services to better understand its customers’ wants and needs and to provide value for its shoppers, KSS Retail said Monday.
“Our customers count on us for great service and value,” Bartell SVP merchandising Ron Miller stated. “We chose KSS Retail because we know price optimization will allow us to better understand what’s important to our shoppers, which will help us deliver the value they’ve come to expect.”
KSS Retail is part of Dunnhumby, a British retail data-analysis company, and also has worked with Kroger, Bi-Lo, United Supermarkets, 7 Eleven and others.
Amneal launches three generic liquid drugs
BRIDGEWATER, N.J. — Generic drug maker Amneal has launched three new liquid drugs, the company said Monday.
Amneal announced the launch of risperidone oral solution, a generic version of Johnson & Johnson’s schizophrenia and bipolar disorder treatment Risperdal, in the 1-mg/mL strength; ondansetron oral solution, a generic version of GlaxoSmithKline’s Zofran used to prevent nausea and vomiting associated with cancer treatment and postoperative recovery, in the 4-mg/5-mL strength; and levetiracetam oral solution, a generic version of UCB Pharma’s epilepsy drug Keppra, in the 100-mg/mL strength. The generic versions of Zofran and Keppra are respectively available in strawberry-scented and grape-flavored liquids.
“Since Amneal’s acquisition of its Branchburg, N.J., liquids plant a few years ago, we have committed significant [research and development] resources to developing a powerful product pipeline in the liquid, nasal spray and topical dosage forms that are now beginning to come to market,” Amneal president Chirag Patel said in a statement. “And the most exciting products are still to come, enhancing an already strong pipeline.”
Upsher-Smith Labs launches topical medication for skin itching and inflammation
MAPLE GROVE, Minn. — Upsher-Smith Labs has launched a topical medication for itching and inflammation of the skin resulting from such conditions as psoriasis and atopic dermatitis, the company said Monday.
Upsher-Smith announced the launch of Trianex (triamcinolone acetonide) ointment, which the company described as a prescription topical corticosteroid that offers the feel of a cream and the strength of an ointment.
“With Trianex, physicians and patients have the best of both worlds: a mid-potency treatment option that delivers the strength of an ointment in a proprietary cream-like base that may be pleasing to patients,” Upsher-Smith director for product marketing Glenn MacEachern stated. “The base for topical corticosteroids is one of many factors that may affect patient compliance, and we are pleased to offer Trianex as a unique option for sufferers of inflammation and itching due to corticosteroid-responsive skin conditions.”